Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability
Introduction Sofosbuvir (SOF) and daclatasvir (DCV) regimens are recommended for all
genotypes of hepatitis C virus (HCV) infection. However, DCV accessibility is still low in …
genotypes of hepatitis C virus (HCV) infection. However, DCV accessibility is still low in …
IL28B rs12979860 polymorphism and zinc supplementation affect treatment outcome and liver fibrosis after direct-acting antiviral hepatitis C therapy
AM Attallah, D Omran, MA Abdelrazek… - Journal of Genetic …, 2021 - Elsevier
Background Impact of interleukin 28B (IL28B) rs12979860 polymorphism on response to
direct-acting antivirals agents in HCV genotype 4-infected patients is under investigation …
direct-acting antivirals agents in HCV genotype 4-infected patients is under investigation …
Direct-acting antiviral treatment of acute hepatitis C virus infections
Introduction: Hepatitis C contributes to significant morbidity and mortality worldwide. AHCV
is defined as documented infection within 6 months of exposure. Treating acute hepatitis C …
is defined as documented infection within 6 months of exposure. Treating acute hepatitis C …
Ribavirin induced anemia: a cross sectional study among patients with hepatitis C, visiting out patient department of a major public sector tertiary care hospital …
ZA Shaikh, J Shamim, K Nankani - Pakistan Journal of Public Health, 2018 - pjph.org
Background: Hepatitis C is among one of the major global health issues; which may cause
chronic liver disease, end stage liver disease, and hepatocellular carcinoma; subsequently …
chronic liver disease, end stage liver disease, and hepatocellular carcinoma; subsequently …
[HTML][HTML] Effectiveness of treatment of chronic viral hepatitis C by direct-acting antivirals in Togo
LM Lawson-Ananissoh, A Bagny, O Bouglouga… - Open Journal of …, 2019 - scirp.org
Background: Viral hepatitis C is the second leading cause of hepatocellular carcinoma after
hepatitis B in Africa and Togo in particular. The advent of direct acting antivirals has …
hepatitis B in Africa and Togo in particular. The advent of direct acting antivirals has …
[PDF][PDF] Comparison of Efficacies of Sofosbuvir/Daclatasvir with Sofosbuvir/Ribavirin for Hepatitis C Virus Genotype 3 Treatment in a Tertiary Care Center in Karachi
S Hussain, SMQ Arfin, I Begum, FN Khan… - History of …, 2024 - researchgate.net
Hepatitis C virus infection (HepCV) is a significant health issue globally, which leads to
several liver diseases, including cirrhosis and hepatocellular carcinomas. There is a class of …
several liver diseases, including cirrhosis and hepatocellular carcinomas. There is a class of …
Infeção pelo vírus da hepatite C: evolução dos modelos de avaliação económica
ALDSF Pinto - 2018 - repositorio.ul.pt
Este estudo teve como objetivo realizar uma revisão sistemática das estruturas e dos
parâmetros chave dos modelos analíticos de decisão apresentados nas avaliações …
parâmetros chave dos modelos analíticos de decisão apresentados nas avaliações …
Study the response of Qurevo (ombitasvir, paritaprevir, and ritonavir) in end-stage renal disease patients with hepatitis C virus
HAE Elshinnawy, II Sarhan, OA Ahmed… - Egyptian Liver …, 2022 - Springer
Background Out of the 185 million people infected with hepatitis C virus (HCV) worldwide
according to the World Health Organization (WHO), Egypt had the highest prevalence of …
according to the World Health Organization (WHO), Egypt had the highest prevalence of …
Ribavirin Induced Anemia among Patients with Hepatitis-C at Tertiary Care Hospital.
ZA Shaikh, J Shamim, AK Bhatti - JMMC, 2019 - mmc.edu.pk
Introduction: Hepatitis C is among one of the major global health issues; which may cause
chronic liver disease, end stage liver disease, and hepatocellular carcinoma; subsequently …
chronic liver disease, end stage liver disease, and hepatocellular carcinoma; subsequently …
Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix …
C Lander, C Brophy - US Patent 10,500,249, 2019 - Google Patents
The described invention provides compositions and methods for reducing progression of a
fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the …
fibrosis in a tissue of a subject selected from liver, kidney or vascular fibrosis, the …